Table 3 Medication use by intervention groups during pregnancy
Medication use, no. (%) | CPAP group N = 153 | Usual-care group N = 157 | p value |
|---|---|---|---|
Antihypertensive agent use, no. (%) | 12 (7.8) | 12 (7.6) | 0.947 |
 Methyldopa, no. (%) | 11 (7.2) | 12 (7.6) | 0.307 |
  Initial dose (mg/day), median (IQR) | 500 (250, 750) | 500 (500, 750) | 0.129 |
  Final dose (mg/day), median (IQR) | 750 (500, 750) | 500 (250, 750) | 0.339 |
 Hydralazine, no. (%) | 3 (25.0) | 8 (66.7) | 0.041 |
  Initial dose (mg/day), median (IQR) | 62.5 (37.5, 87.5) | 50.0 (37.5, 75) | 0.441 |
  Final dose (mg/day), median (IQR) | 75 (37.5, 200) | 75 (50, 75) | 0.267 |
 Combined methyldopa and hydralazine, no. (%) | 2 (16.7) | 8 (66.7) | 0.013 |
 Additional 3rd anti-hypertensive medication, no. (%) | 1 (8.3) | 3 (25.0) | 0.273 |
 MgSO4 stabilization during delivery, no. (%) | 4 (33.3) | 10 (83.3) | 0.013 |
Insulin—no. (%) | 33 (21.6) | 32 (20.4) | 0.798 |
 Insulin dose (u/day), median (IQR) | 32 (3, 160) | 46 (6, 140) | 0.217 |
Other medications | Â | Â | Â |
 Aspirin, no. (%) | 35 (22.9) | 40 (25.5) | 0.593 |
 Calcium supplement, no. (%) | 53 (34.6) | 50 (31.9) | 0.602 |
 Vitamin D supplement, no. (%) | 6 (4.8) | 2 (1.7) | 0.142 |